Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PPM1D | O15297 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465251 | 0.92 | LMNA (0.40) | CTSLCTSSMAPTLMNATP53 | |
| SCHEMBL6473321 | 0.87 | MEN1 (0.40) | CTSLCTSSMAPTLMNAKMT2A | |
| SCHEMBL6463649 | 0.87 | MEN1 (0.40) | CTSLCTSSMAPTLMNAKMT2A | |
| SCHEMBL6466336 | 0.86 | MEN1 (0.40) | CTSLCTSSMAPTLMNAKMT2A | |
| SCHEMBL7043331 | 0.84 | CMA1 (0.46) | CTSLCTSSMAPTLMNA | |
| SCHEMBL6465745 | 0.83 | KMT2A (0.43) | CTSLCTSSLMNATP53KMT2A | |
| SCHEMBL7047599 | 0.82 | CASR (0.41) | CTSLCTSSMAPTLMNAPPM1D | |
| SCHEMBL7186564 | 0.81 | MMP1 (0.39) | CTSLCTSSKMT2A | |
| SCHEMBL7042158 | 0.81 | DAGLA (0.42) | MAPTKMT2A | |
| SCHEMBL7042906 | 0.80 | DAGLA (0.46) | MAPTLMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSL 18/4885CTSS 9/4885MAPT 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.